Eli Rosenbaum Profile
Eli Rosenbaum

@Elirosenbaum11

Followers
32
Following
0
Media
0
Statuses
3

GU oncologist @RabinMedical_ #prostatecancer #bladdercancer #kidneycancer #testicularcancer

Joined September 2022
Don't wanna be here? Send us removal request.
@Elirosenbaum11
Eli Rosenbaum
3 years
PFS of course.
@Elirosenbaum11
Eli Rosenbaum
3 years
Until we have OS results, positive DFS alone is not a surprise since a third active drug was added. Only if the DFS of the triplet is better than ipi+nivo followed by Cabo, it would be a meaningful result and only if significant enough it maybe worth the added toxicity #ESMO22.
0
0
1
@Elirosenbaum11
Eli Rosenbaum
3 years
Until we have OS results, positive DFS alone is not a surprise since a third active drug was added. Only if the DFS of the triplet is better than ipi+nivo followed by Cabo, it would be a meaningful result and only if significant enough it maybe worth the added toxicity #ESMO22.
@tompowles1
Tom Powles
3 years
Cabozantinib/ipilimumab/nivolumab triplet hits DFS primary endpoint (vs ipi/nivo). RR 43% +CR 3% are modest. 32% increase in G3/4 toxicity may be explanation. Benefit seem ⬆️ in intermediate risk pts. OS is going to be important for things to significantly change #ESMO22
Tweet media one
Tweet media two
Tweet media three
Tweet media four
0
0
4
@Elirosenbaum11
Eli Rosenbaum
3 years
As was proved in the STAPEDE, 2 years of ADT and abiraterone with XRT can cure high risk localised PCa (probably also by curing micrometastasis). A subgroup of these salvage XRT patients (who still need to be identified), may need not only longer ADT but also the addition of Abi.
@Prof_Nick_James
Nick James also on @Prof-Nick-James.bsky.social
3 years
Great presentations. More ADT reduces metastatic recurrence but less treatment fine for majority of patients with no OS differences. Need more data to identify who benefits and who needs less therapy.
Tweet media one
Tweet media two
0
0
0